Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

Minister of Medical Care and Sports
PO Box 20350
2500 EJ THE HAGUE

National Health Care Institute
Care II
Infectious Diseases, Blood & Immunology

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact
Ms. J.M. van der Waal
T +31 (0)6 120 017 28

2021013882

Our reference
2021013882

Date 19 April 2021
Subject GVS advice trientine dihydrochloride (Cufence®)

Dear Ms van Ark,

In your letter of 16 March 2021 (CIBG-21-01601), you asked the National Health Care Institute to assess whether the product trientine dihydrochloride (Cufence®) can be included in the Medicine Reimbursement System (GVS). We have handled this request using a marginal review. The considerations are included in the GVS report attached to this letter.

Conclusion of the marginal review
Based on the criteria for interchangeability, it can be concluded that trientine dihydrochloride (Cufence®) is interchangeable with the other medicinal product that is included in the GVS: trientine tetrahydrochloride (Cuprior®).

Advice
We advise you to include trientine dihydrochloride (Cufence®) in the GVS on list 1A in a new cluster to be formed together with trientine tetrahydrochloride (Cuprior®). The standard dose of Cufence® can be determined at 800 mg and that of Cuprior® at 450 mg.

The reimbursement of trientine is subject to a further condition.
The present terms of reimbursement are as follows.
124. Trientine
Condition:
to be used exclusively for insured persons with Wilson's disease for whom therapy with D-penicillamine at the maximum tolerated dose is not sufficient.

These further conditions also apply to Cufence®; the text on List 2 can therefore remain unchanged.

Yours sincerely,

Sjaak Wijma
Chair of the Executive Board